KINS KINGSTONE COMPANIES, INC. Insider Trading

Thomas Newgarden (Director) bought 14,000 shares at $15.21 avg; now -23.4% from 52-week high and below transaction price.

Thomas Newgarden completed 2 separate purchases totaling 14,000 shares for $212,957.60 at an average price of $15.21, increasing his holdings by +16.4% to 99,366 shares post-transaction. The purchases occurred on consecutive days (2026-05-28 and 2026-05-29) at prices of $15.50 and $14.99, during a period when the stock was already -12.3% over 30 days and -9.8% over 90 days. The current price of $14.87 is now below both transaction prices and -23.4% from the 52-week high of $19.42. His same-ticker history shows mixed timing: 3 of 5 prior KINS purchases resulted in positive 90-day returns, but the most recent two purchases (2026-05-13 and 2026-05-12) have shown only modest 30-day and 90-day gains of +3.6% and +2.4% respectively, suggesting recent buys at this ticker have underperformed. The purchases come while the company reports quarterly net income of $-5,808,250.00, and the insider's accumulation into a declining stock in a loss-making period merits observation of whether this represents conviction or automated execution.

Director Newgarden Thomas purchased 30,502 shares at $14.36–$14.52 over two days as stock trades well below 52-week highs; he has a mixed track record at this ticker.

Newgarden Thomas, a director at Kingstone Companies, made consecutive purchases totaling over 30,000 shares over two trading days, bringing his stake up significantly while the stock trades roughly 37% below its 52-week high and has declined over the past month. This is his seventh open-market purchase in three years, continuing a pattern of accumulation with no offsetting sales, though his track record at this specific ticker is mixed—three of his five prior purchases at Kingstone delivered gains within both the near and longer term, while two preceded stock declines. The company itself remains profitable with strong annual revenue growth, and the latest quarterly results show a net loss, though the stock's current valuation appears modest. Newgarden's willingness to deploy capital repeatedly into the same company at depressed prices suggests ongoing conviction, but the mixed outcomes from his prior timing at this ticker—not all of which paid off—warrant monitoring rather than automatic endorsement of his judgment on this stock.